Is Lexiscan (regadenoson) safe for a 75‑year‑old, and what is the risk of myocardial infarction or sudden cardiac death?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Lexiscan Safe for a 75-Year-Old?

Yes, Lexiscan (regadenoson) is generally safe for a 75-year-old patient undergoing myocardial perfusion imaging, though the risk of hypotension is slightly higher in this age group compared to younger patients.

Safety Profile in Elderly Patients

According to the FDA drug label, 56% of patients in clinical trials were ≥65 years old and 24% were ≥75 years old 1. The adverse event profile was similar between older (>75 years) and younger (<65 years) patients, with one notable exception: older patients had a higher incidence of hypotension (2% vs. ≤1%) 1.

Serious Cardiac Risks

Myocardial Infarction and Sudden Cardiac Death

The FDA label explicitly warns that fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred following Lexiscan injection 1. However, these events are rare and typically occur in patients with:

  • Acute myocardial ischemia symptoms
  • Unstable angina
  • Cardiovascular instability

The absolute risk of these catastrophic events in stable outpatients is very low, though post-marketing surveillance has documented cases of asystole and hemodynamic collapse even in stable patients 2, 3.

Heart Block and Arrhythmias

Lexiscan can cause:

  • First-degree AV block (3% of patients)
  • Second-degree AV block (rare, documented in case reports)
  • Third-degree heart block and asystole (post-marketing reports) 1, 3

Lexiscan is absolutely contraindicated in patients with second- or third-degree AV block or sinus node dysfunction unless they have a functioning pacemaker 1.

Practical Risk Assessment

Before administering Lexiscan to your 75-year-old patient, verify:

  1. No active cardiac instability: unstable angina, acute MI symptoms, decompensated heart failure
  2. No high-grade AV block: check baseline ECG for second- or third-degree block
  3. No severe bradycardia: unless pacemaker present
  4. Adequate blood pressure: avoid in severe hypotension or autonomic dysfunction
  5. No recent atrial fibrillation: new-onset or recurrent AF with rapid ventricular response has been reported 1

Safety Data from Recent Studies

A comprehensive safety analysis of 728 consecutive patients (median age 58) showed no deaths, no MI, no VT/VF, and no high-grade AV block 4. The most common symptoms were dyspnea (30%), chest discomfort (27%), and headache (15%)—all self-limited 4.

A 2020 study of 120 patients (mean age 67 years) confirmed that regadenoson is well tolerated with no severe adverse effects observed 5.

Emergency Preparedness

Cardiac resuscitation equipment and trained staff must be available before administering Lexiscan 1. If serious reactions occur:

  • Aminophylline (50-250 mg IV over 30-60 seconds) can reverse the effects as a competitive adenosine antagonist 1
  • Do NOT use aminophylline if seizure occurs 1

Bottom Line

For a stable 75-year-old without contraindications, Lexiscan is safe with a very low risk of MI or sudden cardiac death. The main age-related concern is a slightly increased risk of hypotension (2%). Ensure appropriate patient selection, have resuscitation equipment ready, and avoid use in patients with the specific contraindications listed above. The benefit of accurate ischemia detection typically outweighs the small risk in appropriately selected elderly patients.

References

Research

Asystole following regadenoson infusion in stable outpatients.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2014

Research

Safety and tolerability of regadenoson CMR.

European heart journal. Cardiovascular Imaging, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.